FRIDAY, Aug. 28 (HealthDay News) -- In patients with chronic obstructive pulmonary disease (COPD), an updated BODE index and a new ADO index may be more accurate predictors of mortality and a better guide to clinical practice than the standard BODE index, according to a study published in the Aug. 29 special issue of The Lancet focusing on COPD.
Milo A. Puhan, Ph.D., of the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues assessed the accuracy of the standard BODE index (which includes body mass index, airflow obstruction, dysponea, and exercise capacity) to predict three-year mortality in 232 Swiss patients and 342 Spanish patients. They then updated the BODE index and developed a simplified ADO index (which includes age, dysponea, and airflow obstruction).
The researchers found that the original BODE index under-predicted mortality in the Swiss cohort by 36 percent and over-predicted mortality in the Spanish cohort by 39 percent. However, they found that the three-year mortality risk predicted by both the updated BODE index and the simplified ADO index (10.7 and 11.8 percent, respectively) matched observed mortality in the Spanish cohort.
"Identification of baseline risks through prognostic studies might help to target therapy and can make important and long-needed contributions to, for instance, guideline development," state the authors of an accompanying comment.
The study was partially supported by Novartis Farmaceutica. One researcher reported a past financial relationship with Novartis, and several authors reported financial relationships with other pharmaceutical companies.
Abstract
Full Text (subscription or payment may be required)
Comment (subscription or payment may be required)
